150 related articles for article (PubMed ID: 8601572)
1. Proliferative heterogeneity of human renal cell carcinomas and prevalence of ras gene point mutations.
Waldmann V; Rabes HM
J Cancer Res Clin Oncol; 1996; 122(4):207-13. PubMed ID: 8601572
[TBL] [Abstract][Full Text] [Related]
2. Mutations of the p53 gene and p53 protein overexpression are associated with sarcomatoid transformation in renal cell carcinomas.
Oda H; Nakatsuru Y; Ishikawa T
Cancer Res; 1995 Feb; 55(3):658-62. PubMed ID: 7834636
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
4. Mutation profile of the p53, fhit, p16INK4a/p19ARF and H-ras genes in Indian breast carcinomas.
Kannan K; Krishnamurthy J; Feng J; Nakajima T; Tsuchida N; Shanmugam G
Int J Oncol; 2000 Nov; 17(5):1031-5. PubMed ID: 11029509
[TBL] [Abstract][Full Text] [Related]
5. Infrequent ras oncogene point mutations in renal cell carcinoma.
Nanus DM; Mentle IR; Motzer RJ; Bander NH; Albino AP
J Urol; 1990 Jan; 143(1):175-8. PubMed ID: 2403598
[TBL] [Abstract][Full Text] [Related]
6. Cyclin A and MIB1 (Ki67) as markers of proliferative activity in primary renal neoplasms.
Renshaw AA; Loughlin KR; Dutta A
Mod Pathol; 1998 Oct; 11(10):963-6. PubMed ID: 9796723
[TBL] [Abstract][Full Text] [Related]
7. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.
Hruban RH; van Mansfeld AD; Offerhaus GJ; van Weering DH; Allison DC; Goodman SN; Kensler TW; Bose KK; Cameron JL; Bos JL
Am J Pathol; 1993 Aug; 143(2):545-54. PubMed ID: 8342602
[TBL] [Abstract][Full Text] [Related]
8. Absence of ras family point mutations at codons 12, 13 and 61 in N-ethyl-N-hydroxyethylnitrosamine- or N-nitrosomorpholine-induced renal cell tumors in rats.
Matsumoto K; Tsuda H; Iwase T; Ito M; Nishida Y; Oyama F; Titani K; Ushijima T; Nagao M; Hirono I
Jpn J Cancer Res; 1992 Sep; 83(9):933-6. PubMed ID: 1429202
[TBL] [Abstract][Full Text] [Related]
9. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
10. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
11. Absence of Ki-ras mutations in exocrine pancreatic tumors from male rats chronically exposed to gabapentin.
Fowler ML; Sigler RE; de la Iglesia FA; Reddy JK; Lalwani ND
Mutat Res; 1995 Mar; 327(1-2):151-60. PubMed ID: 7870083
[TBL] [Abstract][Full Text] [Related]
12. K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients.
Cuatrecasas M; Erill N; Musulen E; Costa I; Matias-Guiu X; Prat J
Cancer; 1998 Mar; 82(6):1088-95. PubMed ID: 9506354
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of activating ras mutations in morphologically characterized thyroid nodules.
Ezzat S; Zheng L; Kolenda J; Safarian A; Freeman JL; Asa SL
Thyroid; 1996 Oct; 6(5):409-16. PubMed ID: 8936664
[TBL] [Abstract][Full Text] [Related]
14. "Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases.
Stenzel A; Semczuk A; Rózyńskal K; Jakowicki J; Wojcierowski J
Pathol Res Pract; 2001; 197(9):597-603. PubMed ID: 11569923
[TBL] [Abstract][Full Text] [Related]
15. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors.
Capella G; Cronauer-Mitra S; Pienado MA; Perucho M
Environ Health Perspect; 1991 Jun; 93():125-31. PubMed ID: 1685441
[TBL] [Abstract][Full Text] [Related]
16. Analysis of proliferative compartments in human tumors. I. Renal adenocarcinoma.
Rabes HM; Carl P; Meister P; Rattenhuber U
Cancer; 1979 Sep; 44(3):799-813. PubMed ID: 476595
[TBL] [Abstract][Full Text] [Related]
17. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung.
Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H
Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992
[TBL] [Abstract][Full Text] [Related]
18. Low frequency of alterations in p53, K-ras, and mdm2 in rat lung neoplasms induced by diesel exhaust or carbon black.
Swafford DS; Nikula KJ; Mitchell CE; Belinsky SA
Carcinogenesis; 1995 May; 16(5):1215-21. PubMed ID: 7539340
[TBL] [Abstract][Full Text] [Related]
19. Detection of K-ras mutations in stools of patients with colorectal cancer by mutant-enriched PCR.
Nollau P; Moser C; Weinland G; Wagener C
Int J Cancer; 1996 May; 66(3):332-6. PubMed ID: 8621253
[TBL] [Abstract][Full Text] [Related]
20. Effects of K-ras gene mutations in the development of lung lesions induced by 4-(N-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone in A/J mice.
Kawano R; Takeshima Y; Inai K
Jpn J Cancer Res; 1996 Jan; 87(1):44-50. PubMed ID: 8609047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
